Phaseline

Targets › GUCY2C

GUCY2C (Guanylyl cyclase C): drug programs, companies and trials

8 programs from 7 companies in 9 trials: 6 Phase 1, 2 Phase 2, 1 Phase 4; Oncology, Other, Metabolic and endocrine; next expected readout Nov 2026.

Guanylyl cyclase that catalyzes synthesis of cyclic GMP (cGMP) from GTP. Receptor for the E.coli heat-stable enterotoxin; E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GUCY2C. Also activated by the endogenous peptides guanylin and uroguanylin. (UniProt, P25092)

Open in Phaseline: the race on GUCY2C, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Texas Tech University Health Sciences Center, El Pasolinaclotide
Heat-stable enterotoxin receptor agonist
GUCY2CPhase 4Chronic ConstipationJan 2027
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityLinaclotide
Heat-stable enterotoxin receptor agonist
GUCY2CPhase 2Colorectal AdenomaNov 2026
Bausch Health Americasplecanatide
Heat-stable enterotoxin receptor agonist
GUCY2CPhase 2Functional Constipation (FC)Oct 2027
Beijing BiotechEB-DUO-CAR-NK-CEA/GCC
Dual-target CAR-NK cell therapy targeting CEA and GUCY2C (or CEA and HER2, or GUCY2C and H
CEACAM5, GUCY2C, ERBB2, CEA, HER2, IL15Phase 1Colorectal Cancer; Colorectal Cancer MetastaticMar 2027
Thomas Jefferson UniversityAd5.F35-hGUCY2C-PADRE vaccine
Adenovirus 5 vector expressing human GUCY2C antigen with PADRE epitope for cancer immunoth
GUCY2CPhase 1Colorectal CancerOct 2027
Thomas Jefferson UniversityLm-GUCY2C vaccine
Recombinant Listeria monocytogenes expressing human GUCY2C antigen for cancer immunotherap
GUCY2CPhase 1Colorectal CancerOct 2027
Second Affiliated Hospital of Guangzhou Medical UniversityMesothelin/GPC3/GUCY2C-CAR-T cells
CAR-T cells targeting mesothelin, GPC3, and GUCY2C; second generation with IL-21/anti-PD-1
MSLN, GPC3, GUCY2CPhase 1Pancreas CancerMar 2029
University of FloridaLinaclotide
Heat-stable enterotoxin receptor agonist
GUCY2CPhase 1Patients Scheduled for Colonoscopy–

Conditions

Colorectal Cancer (3) Colorectal Cancer Metastatic (1) Colorectal Adenoma (1) Patients Scheduled for Colonoscopy (1) Chronic Constipation (1) Functional Constipation (FC) (1) Pancreas Cancer (1)

Modalities

other (3), protein or peptide (3), mixed (1), small molecule (1)

Companies

Thomas Jefferson University (2) Beijing Biotech (1) Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) University of Florida (1) Texas Tech University Health Sciences Center, El Paso (1) Bausch Health Americas (1) Second Affiliated Hospital of Guangzhou Medical University (1)

Related targets

CEACAM5 (1) ERBB2 (1) CEA (1) HER2 (1) IL15 (1) MSLN (1) GPC3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.